Cartesian Therapeutics, Inc. - Common Stock RNAC 深 沪
已收盘 08-01 16:00:00 美东时间
12.33
-0.480
-3.75%
华盛通- 最 高13.10
- 今 开12.56
- 成交量 7.79万股
- 最 低 12.06
- 昨 收 12.81
- 总市值 3.20亿
- 52周最高 26.50
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 8.46
- 委 比 90.51%
- 总股本 2595.43万
- 历史最高 840.00
- 量 比 1.28
- 振 幅 8.12%
- 历史最低 8.46
- 每 手 1
- 风险率 6.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
07-25 01:08
Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.
07-09 18:55
Cartesian Therapeutics Holds Annual Stockholders Meeting
Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On June 13, 2025...
06-16 19:28
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, a clinical-stage biotech company, announced the granting of inducement awards to three new employees, including options to purchase 26,350 shares with an exercise price of $9.98 under its 2018 Employment Inducement Incentive Award Plan. The options vest 25% on June 2, 2026, followed by three equal annual installments, fully vesting by 2029, with a 10-year term. The company is focused on pioneering cell therapy for autoimmu...
06-03 11:05
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
Cartesian Therapeutics has啟動其Descartes-08的三期AURORA試驗，這是針對全身性重症肌无力的首款CAR-T療法。首位患者已入組，將評估其療效及安全性。Descartes-08無需預處理化療，適用於門診治療。該療法已在二期研究中展示出持久的應答，平均MG-ADL評分改善顯著。試驗將隨機對照，規模約100例患者，主要終點為三個月時的評分改善情況。公司หวัง藉此改進現有的MG治療方案，提供更安全、持久的選擇。
05-30 11:00
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?
HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.
05-28 03:42
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40
Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $41 to $40.
05-09 02:57
Cartesian Therapeutics Q1 EPS $(0.68) Beats $(0.71) Estimate, Sales $1.10M Beat $785.71K Estimate
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.71) by 4.23 percent. This is a 93.52 percent increase over losses of $(10.50) per share
05-08 21:15
